Back to discover
Drug

Hydrogen Peroxide

Regulatory activity · MHRA
Emerging researchLate-stage developmentRising momentum
Also known as ActiveOxy, Astri-UC, Eskata, Oxy Gard+16 more

ActiveOxy, Astri-UC, Eskata, Oxy Gard, Oxycide, Perimax Perio Rinse, Periogel, Perox-A-Mint, Peroxi-Fresh, Peroxide D'hydrogene, Peroxy Shield, Peroxyde D'hydrogene, Peroxyl, Preop, Proxacol, Pur-Oxy, Superoxol, Teat Dip-HP10, Hydrogen dioxide, Hydroperoxide.

11
Research papers
2
Active clinical trials
1
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Antiseptic Effects on the Dental Implant Internal Surface Microbiome

Clinical trial2026-07-22Status changed to Completed · ClinicalTrials.gov

Evaluation of Aerosol in a Dental Clinic

Clinical trial2025-07-08Results posted · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Hydrogen Peroxide
Aliases & brands
ActiveOxyAstri-UCEskataOxy GardOxycidePerimax Perio RinsePeriogelPerox-A-MintPeroxi-FreshPeroxide D'hydrogenePeroxy ShieldPeroxyde D'hydrogenePeroxylPreopProxacolPur-OxySuperoxolTeat Dip-HP10Hydrogen dioxideHydroperoxide
RxNorm CUI
5499
ChEMBL ID
CHEMBL71595
ATC codes
A01AB02D11AX25D08AX01S02AA06
UNII
BBX060AN9V
Regulatory jurisdictions
mhra

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Authorities
MHRA
Total events
1
mhraMedicines and Healthcare products Regulatory Agency· 1 event
2014-12-19Safety communicationSafety
Drug Safety Update: Hydrogen peroxide: reminder of risk of gas embolism when used in surgery
Evidence ↗

Contains public sector information from the Medicines and Healthcare products Regulatory Agency (MHRA) licensed under the Open Government Licence (OGL v3).

Clinical trials

13 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
13
registered trials across all phases
LATEST COMPLETION 2026
2
Active studies
1
Recruiting
7
Late-stage (III+)
10
Completed
1
Discontinued
PHASE DISTRIBUTIONn = 13
Early Phase 12Phase 1 / 21Phase 23Phase 31Phase 42Phase N / A4

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Recent completions

Trials that read out recently, adding to the completed evidence base.

Research activity

11 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20112024
Most influential
Recent papers
Major research themes8
Antioxidants3Hydrogen Peroxide3Neoplasms2Oxidative Stress2Apoptosis1Bacterial Proteins1Catalase1Cystine1
Journals, researchers & institutions
Top journals
  • Archives of toxicology1
  • Biomolecules1
  • Brain : a journal of neurology1
  • Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology1
  • eLife1
  • Frontiers in immunology1
Leading researchers
  • Ali Q1
  • Alomar SY1
  • Alrumaihi F1
  • Alwasel SH1
  • Anwar S1
  • Ashfaq M1
  • Babiker AY1
  • Bista P1
Leading institutions
free-text, unnormalised
  • Bioelectronics Materials and Devices Laboratory1
  • Biomedical Research Center1
  • Center for Computational and Integrative Biology and Department of Computer Science1
  • Center for Free Radical Biology1
  • College of Applied Medical Sciences1
  • College of Science1

Related diseases

1 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Active research areas

Related drugs

8 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Studied across 4 of the same disease areas as Hydrogen Peroxide in the shared literature.

4 shared diseases3 shared papers

Studied across 3 of the same disease areas as Hydrogen Peroxide in the shared literature.

3 shared diseases1 shared paper

Studied across 3 of the same disease areas as Hydrogen Peroxide in the shared literature.

3 shared diseases1 shared paper

Studied across 2 of the same disease areas as Hydrogen Peroxide in the shared literature.

2 shared diseases1 shared paper

Studied across the same disease area as Hydrogen Peroxide in the shared literature.

1 shared disease1 shared paper

Studied across the same disease area as Hydrogen Peroxide in the shared literature.

1 shared disease1 shared paper

Frequently co-studied with Hydrogen Peroxide in the research literature.

1 shared paper

Frequently co-studied with Hydrogen Peroxide in the research literature.

1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.